Heron Therapeutics, Inc.


Biopharmaceutical company focused on developing and commercializing reformulated and extended‑release versions of approved pharmacological agents for acute care and oncology supportive care. Activities include formulation development for parenteral delivery, clinical development (Phase 2/3), regulatory submissions and commercialization of FDA‑approved injectable and extended‑release products, and medical information and investigator‑initiated trial support for healthcare professionals.

Industries

Biotechnology
Health Care
Therapeutics
Healthcare Services & Hospitals
Healthcare
Biotechnology Research

Nr. of Employees

medium (51-250)

Heron Therapeutics, Inc.

Cary, North Carolina, United States


Patents

Compositions of a polyorthoester and an aprotic solvent

US-12318376-B2

View Details

Methods of use of emulsion formulations of aprepitant

US-12290520-B2

View Details

Methods of use of emulsion formulations of an NK-1 receptor antagonist

US-12115255-B2

View Details

Methods of use of emulsion formulations of an NK-1 receptor antagonist

US-12115254-B2

View Details

Methods of use of emulsion formulations of an NK-1 receptor antagonist

US-11878074-B2

View Details

Compositions of a polyorthoester and an organic acid excipient

US-11844837-B2

View Details
View All Patents

Products

CINVANTI (aprepitant) injectable emulsion

A neurokinin‑1 (NK1) receptor antagonist formulated as an injectable emulsion for prevention of acute and delayed chemotherapy‑induced nausea and vomiting; available as 30‑minute infusion and 2‑minute IV push.

ZYNRELEF (bupivacaine and meloxicam) extended‑release solution

A fixed‑dose dual‑acting extended‑release local analgesic combining bupivacaine and meloxicam for instillation into the surgical wound to provide postsurgical analgesia for up to 72 hours.

SUSTOL (granisetron) extended‑release injection

A serotonin‑3 (5‑HT3) receptor antagonist in an extended‑release injectable formulation indicated for prevention of acute and delayed nausea and vomiting associated with certain chemotherapy regimens.

APONVIE (aprepitant) injectable emulsion

An injectable formulation of aprepitant indicated for prevention of postoperative nausea and vomiting (PONV); administered as a short IV infusion and bioequivalent to oral aprepitant.

SUSTOL

SUSTOL is a subcutaneous injection approved for the prevention of chemotherapy-induced nausea and vomiting (CINV).

ZYNRELEF

ZYNRELEF is indicated for postoperative pain management and is approved in the U.S., Canada, and 31 European countries.

View All Products

Services

Respond to medical inquiries from U.S. healthcare professionals via an online form and telephone contact; includes distribution of prescribing information and reprints.

Funding review and support for investigator‑initiated trials, medical education grants, sponsorships, and contributions focused on oncology and postoperative pain management; application forms provided online.

Provision of publications and clinical resources to support evidence‑based use of products and to inform healthcare professionals.

Expertise Areas

  • Clinical trial management
  • Formulation development for parenteral delivery
  • Extended‑release drug delivery
  • Oncology supportive care (antiemetics)
  • Show More (5)

Key Technologies

  • Extended‑release drug delivery
  • Injectable emulsion formulation
  • Parenteral administration (IV push, IV infusion, subcutaneous)
  • Dual‑acting local anesthetic + NSAID combination formulation
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.